AU2003245858A1 - Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases - Google Patents

Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Info

Publication number
AU2003245858A1
AU2003245858A1 AU2003245858A AU2003245858A AU2003245858A1 AU 2003245858 A1 AU2003245858 A1 AU 2003245858A1 AU 2003245858 A AU2003245858 A AU 2003245858A AU 2003245858 A AU2003245858 A AU 2003245858A AU 2003245858 A1 AU2003245858 A1 AU 2003245858A1
Authority
AU
Australia
Prior art keywords
ngal
diagnosis
treatment
binding substances
cancer diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003245858A
Other versions
AU2003245858A8 (en
Inventor
Edgar Dahl
Esmeralda Heiden
Bernd Hinzmann
Irina Klamann
Rosemarie Lichtner
Christian Pilarsky
Andre Rosenthal
Thomas Specht
Anke Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metagen Pharmaceuticals GmbH
Original Assignee
Metagen Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagen Pharmaceuticals GmbH filed Critical Metagen Pharmaceuticals GmbH
Publication of AU2003245858A8 publication Critical patent/AU2003245858A8/en
Publication of AU2003245858A1 publication Critical patent/AU2003245858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AU2003245858A 2002-07-02 2003-06-12 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases Abandoned AU2003245858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230631.1 2002-07-02
DE10230631A DE10230631A1 (en) 2002-07-02 2002-07-02 Uses of Ngal-binding substances for the diagnosis and treatment of cancer
PCT/DE2003/001986 WO2004005540A2 (en) 2002-07-02 2003-06-12 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Publications (2)

Publication Number Publication Date
AU2003245858A8 AU2003245858A8 (en) 2004-01-23
AU2003245858A1 true AU2003245858A1 (en) 2004-01-23

Family

ID=29761726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003245858A Abandoned AU2003245858A1 (en) 2002-07-02 2003-06-12 Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Country Status (3)

Country Link
AU (1) AU2003245858A1 (en)
DE (1) DE10230631A1 (en)
WO (1) WO2004005540A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086638A2 (en) * 2005-02-10 2006-08-17 Board Of Regents, The University Of Texas System Targeting lipocalin-2 for cancer therapeutics
JP2010502985A (en) * 2006-09-05 2010-01-28 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド Use of lipocalin 2 in the control of insulin sensitivity
EP2209803A1 (en) * 2007-10-19 2010-07-28 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
EP2344526A1 (en) 2008-11-05 2011-07-20 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
GB201016852D0 (en) * 2010-10-07 2010-11-17 Univ York Cell differentiation
CN109709340B (en) * 2018-12-29 2022-02-11 江苏众红生物工程创药研究院有限公司 Human neutrophil gelatinase-associated lipocalin quantitative detection card and clinical application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846739A (en) * 1995-12-05 1998-12-08 Wisconsin Alumni Research Foundation Immunohistochemical detection assay for carcinoma proliferative status
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
DE19817557A1 (en) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian tumor tissue
WO2001049716A2 (en) * 1999-12-30 2001-07-12 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2001294617A1 (en) * 2000-09-21 2002-04-02 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005508144A (en) * 2001-06-18 2005-03-31 イオス バイオテクノロジー，インコーポレイティド Ovarian cancer diagnostic method, composition and method for screening ovarian cancer modulator

Also Published As

Publication number Publication date
AU2003245858A8 (en) 2004-01-23
DE10230631A1 (en) 2004-01-22
WO2004005540A3 (en) 2004-09-16
WO2004005540A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
HK1162948A1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin)
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1587837A3 (en) Prostate cancer diagnosis and treatment
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003205913A1 (en) Materials and methods relating to cancer diagnosis
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase